<DOC>
	<DOCNO>NCT02748642</DOCNO>
	<brief_summary>This single-center , randomize , observer-blinded , placebo-controlled , single multiple ascending-dose study conduct two part evaluate safety , pharmacokinetics , immunogenicity BITS7201A . Part A ascending , single-dose , sequential-group study participant randomly assign active drug placebo . Part B ascending , multiple-dose , sequential-group study participant randomize active drug placebo . Total length study anticipate approximately 12 month .</brief_summary>
	<brief_title>A Study Investigate Safety , Pharmacokinetics , Immunogenicity BITS7201A Healthy Volunteers Participants With Mild Atopic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>General Body mass index ( BMI ) 18 37 kilogram per meter square ( kg/m^2 ) Weight 50120 kg Participants good health , determine clinically significant finding medical history , 12lead electrocardiogram ( ECG ) , vital sign Clinical laboratory evaluation within reference range test laboratory unless deem clinically significant Investigator Sponsor . For woman childbearing potential : agreement remain abstinent ( refrain heterosexual intercourse ) use highly effective contraceptive method least 70 day last dose study drug For men : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure , agreement refrain donate sperm least 70 day last dose study drug Additional Inclusion Criteria Participants With Mild Atopic Asthma : Diagnosis asthma great equal ( &gt; /= ) 12 month prior screen History atopy Positive bronchodilator reversibility test screen documentation positive bronchodilator reversibility test perform within 2 year screen documentation positive bronchial challenge test within 5 year Prebronchodilator force expiratory volume 1 second ( FEV1 ) &gt; /=70 percent ( % ) predict screen Fractional exhale nitric oxide ( FeNO ) &gt; /=30 part per billion ( ppb ) screen randomization ( predose ) Mild atopic asthma participant mild , stable disease General History clinical manifestation significant metabolic , hepatic , renal , pulmonary , cardiovascular , gastrointestinal , urologic , neurologic disorder History hematologic immunosuppressive disorder History psychiatric disorder History inflammatory bowel disease History anaphylaxis , hypersensitivity , significant drug allergy History presence abnormal ECG , clinically significant History positive tuberculin skin test Participants neutropenia thrombocytopenia History alcoholism drug addiction within 1 year screening Selfreported history smoking ( tobacco marijuana ) within 7 day prior initiation study drug Smokers able pas tobaccorelated laboratory screen refrain smoking confinement period Pregnancy lactation History malignancy , except completely excise basal cell carcinoma squamous cell carcinoma skin Any severe bacterial , fungal , parasitic infection associate hospitalization intravenous ( IV ) antibiotic within 1 year screen History active parasitic infection within 6 month exposure waterborn parasite within 6 week prior initiation study drug Upper low respiratory tract infection within 4 week prior screen Received oral antibiotic within 4 week prior initiation study drug , IV/intramuscular ( IM ) antibiotic within 8 week prior initiation study drug Use prescription medications/products ( except asthma medication prescribe prior study entry ) within 7 day prior Day 1 throughout study Use immunosuppressive medication within 30 day 5 halflives , whichever great , prior initiation study drug Use nonbiologic investigational drug participation investigational study nonbiologic drug within 30 day prior initiation study drug ( within 5 halflives investigational product , whichever great ) Use biologic investigational therapy participation investigational study involve biologic therapy within 3 month 5 halflives , whichever great , prior initiation study drug Received live attenuate vaccine within 30 day prior screen Received kill vaccine within 7 day prior initiation study drug , unless deem acceptable investigator Sponsor Positive blood test chronic viral infection : hepatitis B surface antigen , hepatitis C virus antibody , human immunodeficiency virus ( HIV ) antibody Additional Exclusion Criteria Participants With Mild Atopic Asthma : Active lung disease asthma Occupations potential exposure exogenous source nitrous oxide and/or associate elevated FeNO Unable perform FeNO measurement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>